CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
(±)-Enitociclib
CAS:<p>(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.</p>Fórmula:C19H18F2N4O2SPureza:99.29%Forma y color:SolidPeso molecular:404.43Garcinone C
CAS:<p>Garcinone C, a xanthone from Garcinia oblongifolia, is anti-inflammatory, promotes healing, and may fight some cancers.</p>Fórmula:C23H26O7Pureza:99.13% - 99.92%Forma y color:SolidPeso molecular:414.45Nimbolide
CAS:<p>Nimbolide, from neem, inhibits CDK4/6, NF-κB, Wnt, PI3K-Akt, MAPK, JAK-STAT pathways and induces apoptosis.</p>Fórmula:C27H30O7Pureza:95.84% - 99.4%Forma y color:SolidPeso molecular:466.52Amantadine hydrochloride
CAS:<p>Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.</p>Fórmula:C10H18ClNPureza:99.98%Forma y color:Solid CrystallinePeso molecular:187.71Simurosertib
CAS:<p>Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).</p>Fórmula:C17H19N5OSPureza:99.93% - 99.93%Forma y color:SolidPeso molecular:341.43CDK4/6-IN-2
CAS:<p>CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。</p>Fórmula:C27H32F2N8Pureza:99.47%Forma y color:SolidPeso molecular:506.59hSMG-1 inhibitor 11j
CAS:<p>hSMG-1 inhibitor 11j: pyrimidine, IC50=0.11 nM, >455x selective vs. mTOR/PI3Kα/γ/CDK1/CDK2; cancer research use.</p>Fórmula:C27H28ClN7O3SPureza:99.22% - 99.65%Forma y color:SolidPeso molecular:566.07BRD6989
CAS:<p>BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.</p>Fórmula:C16H16N4Pureza:99.43%Forma y color:SolidPeso molecular:264.33Avotaciclib
CAS:<p>Avotaciclib (BEY1107) is a potent and orally active cyclin dependent kinase 1 (CDK1) inhibitor.Avotaciclib can be used to study locally advanced or metastatic</p>Fórmula:C13H11N7OPureza:98.02%Forma y color:SolidPeso molecular:281.27CDKI-73
CAS:<p>CDKI-73: strong CDK9 blocker, Ki 4 nM, kills CLL cells selectively, aids cisplatin.</p>Fórmula:C15H15FN6O2S2Pureza:98.11%Forma y color:SolidPeso molecular:394.45Lerociclib dihydrochloride
CAS:<p>Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/</p>Fórmula:C26H36Cl2N8OPureza:97.4%Forma y color:SolidPeso molecular:547.52Ca2+ channel agonist 1
CAS:<p>Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.</p>Fórmula:C19H26N6OPureza:97.71%Forma y color:SolidPeso molecular:354.45Cirtuvivint
CAS:<p>Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.</p>Fórmula:C24H25N7OPureza:99.46% - >99.99%Forma y color:SolidPeso molecular:427.5XPW1
CAS:<p>XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.</p>Fórmula:C36H39ClFN7O2Pureza:98.08%Forma y color:SoildPeso molecular:656.19MBQ-167
CAS:<p>MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).</p>Fórmula:C22H18N4Pureza:98.07% - 99.52%Forma y color:SolidPeso molecular:338.41Cyclin K degrader 1
<p>Cyclin K degrader 1 is a Cyclin K degrader.Cyclin K degrader 1 is a degrader converted from AT-7519.Cyclin K degrader 1 has weak degrading activity against Cyclin K but does not result in a sustained decrease in degradation affinity.Cyclin K degrader 1 is a degrader converted from AT-7519.</p>Fórmula:C23H17Cl2N5O2Pureza:99.76%Forma y color:SolidPeso molecular:466.32NU6140
CAS:<p>NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).</p>Fórmula:C23H30N6O2Pureza:98.33%Forma y color:SolidPeso molecular:422.52NVP-2
CAS:<p>NVP-2 selectively inhibits CDK9 (IC50: 0.514 nM), prompts apoptosis, and affects other CDKs (IC50: 0.584-0.706 μM).</p>Fórmula:C27H37ClN6O2Pureza:99.13%Forma y color:SolidPeso molecular:513.07Ribociclib succinate
CAS:<p>Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Fórmula:C27H36N8O5Pureza:99.9%Forma y color:SolidPeso molecular:552.63(R)-CR8
CAS:<p>(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.</p>Fórmula:C24H29N7OPureza:98.41%Forma y color:SolidPeso molecular:431.53Trilaciclib hydrochloride
CAS:<p>Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).</p>Fórmula:C24H32Cl2N8OPureza:99.69% - 99.89%Forma y color:SolidPeso molecular:519.47CDK2-IN-4
CAS:<p>CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.</p>Fórmula:C23H18N6O2SPureza:97.24% - 99.10%Forma y color:SolidPeso molecular:442.49Samuraciclib hydrochloride
CAS:<p>Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).</p>Fórmula:C22H31ClN6OPureza:98.99% - 99.8%Forma y color:SolidPeso molecular:430.97Cdk2/Cyclin Inhibitory Peptide II
CAS:<p>Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].</p>Fórmula:C110H200N48O25Forma y color:SolidPeso molecular:2595.07CDK2-IN-7
CAS:<p>CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).</p>Fórmula:C24H30N6O4SForma y color:SolidPeso molecular:498.6PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Fórmula:C43H51FN12O7Forma y color:SolidPeso molecular:866.94SNX7
CAS:<p>SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.</p>Fórmula:C15H14N2OPureza:99.05%Forma y color:SolidPeso molecular:238.28CDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Fórmula:C20H21F2N9Forma y color:SolidPeso molecular:425.448CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Fórmula:C32H34FN7O4Forma y color:SolidPeso molecular:599.655FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidCAF-382
<p>CAF-382 (compound B1), an analog of SNS-032, functions as a CDKL5 and pan-CDK inhibitor, exhibiting modest inhibitory activity against GSK3α/β with an affinity</p>Fórmula:C16H22N4O2S2Pureza:98%Forma y color:SolidPeso molecular:366.5CDK9 inhibitor HH1
CAS:<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Fórmula:C13H15N3OSPureza:99.92%Forma y color:SolidPeso molecular:261.34TMX-2138
CAS:<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Fórmula:C40H43BrFN9O11SForma y color:SolidPeso molecular:956.791CDK-IN-15
CAS:<p>CDK-IN-15 (Compound 456) is an effective inhibitor of Cyclin A, exhibiting an IC50 value of 0.14 μM.</p>Fórmula:C45H63Cl2F4N7O8Forma y color:SolidPeso molecular:976.92Anticancer agent 264
<p>Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.</p>Fórmula:C23H18ClF5N6OForma y color:SolidPeso molecular:524.87PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Fórmula:C40H42N12O5Peso molecular:770.34011Olomoucine
CAS:<p>Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.</p>Fórmula:C15H18N6OPureza:99.77%Forma y color:White Crystalline PowderPeso molecular:298.34Cell Cycle Compound Library
<p>A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Forma y color:Odour SolidPROTAC CDK9 degrader-8
<p>PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].</p>Fórmula:C44H52Cl2N10O7Pureza:98%Forma y color:SolidPeso molecular:903.85PROTAC CDK9 degrader-7
CAS:<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Fórmula:C43H50Cl2N8O9Forma y color:SoildPeso molecular:893.81AM5992
CAS:<p>AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders.</p>Fórmula:C27H33FN8OPureza:98%Forma y color:SoildPeso molecular:504.6[Ala92]-p16 (84-103)
CAS:<p>Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.</p>Fórmula:C93H155N31O26Pureza:98%Forma y color:SolidPeso molecular:2123.44CDK7-IN-21
CAS:<p>CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .</p>Fórmula:C33H36FN9O2Forma y color:SolidPeso molecular:609.7XY028-133
CAS:<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Fórmula:C53H67N11O7SPureza:97.11%Forma y color:SolidPeso molecular:1002.23EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Fórmula:C30H20N6OSPureza:98%Forma y color:SolidPeso molecular:512.58JHD205
<p>JHD205 is an inhibitor of CDK4/6.</p>Fórmula:C32H40F2N8OForma y color:SolidPeso molecular:590.71CDK9-IN-25
<p>CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.</p>Fórmula:C15H16FN5Pureza:98%Forma y color:SolidPeso molecular:285.32Cimpuciclib
CAS:<p>Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.</p>Fórmula:C30H35FN8OForma y color:SolidPeso molecular:542.663[pThr3]-CDK5 Substrate
CAS:<p>[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].</p>Fórmula:C53H100N15O15PPureza:98%Forma y color:SolidPeso molecular:1218.43CDK4/6-IN-11
CAS:<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Fórmula:C43H49N11O7Forma y color:SolidPeso molecular:831.92dCeMM3
CAS:<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Fórmula:C14H11ClN4OSPureza:98.48% - 99.41%Forma y color:SolidPeso molecular:318.78CP-07
<p>CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formation</p>Fórmula:C45H48N6O8Pureza:98%Forma y color:SolidPeso molecular:800.9CDK2-IN-19
<p>CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].</p>Fórmula:C20H21FN6O4SPureza:98%Forma y color:SolidPeso molecular:460.48HTH-01-091 TFA
<p>HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.</p>Fórmula:C28H29Cl2F3N4O4Forma y color:SolidPeso molecular:613.46(E/Z)-THZ1 2HCl
CAS:<p>THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.</p>Fórmula:C31H30Cl3N7O2Pureza:99.51%Forma y color:SolidPeso molecular:638.98CDK9-IN-35
<p>CDK9-IN-35 (compound 10j) acts as an inhibitor of CDK9/CyclinT1, exhibiting an IC50 of 10.2 nM. It also shows an IC50 of 20 nM against the HCT-116 cell line.</p>Fórmula:C26H24ClFN4O4SForma y color:SolidPeso molecular:543.01CDK2/PIM1-IN-1
<p>CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.</p>Forma y color:Odour SolidMeBIO
CAS:<p>MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.</p>Fórmula:C17H12BrN3O2Pureza:99.64%Forma y color:SolidPeso molecular:370.2CDK7-IN-6
CAS:<p>CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.</p>Fórmula:C26H34ClN9OForma y color:SolidPeso molecular:524.07[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Fórmula:C98H138F3N21O39Pureza:98%Forma y color:SolidPeso molecular:2291.25LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Fórmula:C37H43N5OForma y color:SolidPeso molecular:573.77Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidCdk2/Cyclin Inhibitory Peptide I
<p>CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.</p>Fórmula:C111H196N48O23Pureza:98%Forma y color:SolidPeso molecular:2571.05Maleimide-PEG8-Val-Ala-PAB-SNS032
<p>Maleimide-Val-Ala-PAB-SNS032 is a conjugated compound used as an ADC toxin and linker. SNS032 acts as a CDK inhibitor, reducing cancer cell viability and arresting the cell cycle at the G1/S phase. Maleimide-Val-Ala-PAB functions as a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 is utilized in the synthesis of ADC molecules.</p>Fórmula:C59H87N9O18S2Peso molecular:1273.56105Men 10376
CAS:<p>Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.</p>Fórmula:C57H68N12O10Pureza:98%Forma y color:SolidPeso molecular:1081.22JWZ-5-13
<p>JWZ-5-13 is an effective CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 also exhibits antitumor activity.</p>Fórmula:C54H66N10O6SPeso molecular:982.48875Eciruciclib
CAS:<p>Eciruciclib is an inhibitor of CDK with antitumor properties.</p>Fórmula:C27H33FN8Pureza:99.73%Forma y color:SolidPeso molecular:488.6CPS2
CAS:<p>CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.</p>Fórmula:C38H42N12O10S2Forma y color:SolidPeso molecular:890.94JH-XVI-178
CAS:<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Fórmula:C22H22ClN7OForma y color:SolidPeso molecular:435.92SHR5428
<p>SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressing</p>Pureza:98%Forma y color:Odour SolidJH-XI-10-02
CAS:<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161CDK7-IN-5
CAS:<p>CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).</p>Fórmula:C34H45N9O2Forma y color:SolidPeso molecular:611.795CDK2-IN-20
<p>CDK2-IN-20 (compound 3b), a CDK2 inhibitor, exhibits cytotoxic effects on tumor cells with an IC50 ranging from 5.52-17.09 µM.</p>Pureza:98%Forma y color:Odour SolidBSJ-03-204
CAS:<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Fórmula:C43H48N10O8Forma y color:SolidPeso molecular:832.9CDK9 degrader-1
<p>CDK9degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). It recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuse with lysosomes to degrade CDK9 and its partner protein, Cyclin T1 (DC50: 1.215 µM). CDK9degrader-1 induces caspase 3-mediated apoptosis and exhibits antitumor activity in a mouse HCT116 xenograft model.</p>Fórmula:C32H34Cl2N6O4Forma y color:SolidPeso molecular:637.56PROTAC CDK9 degrader-2
CAS:<p>PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.</p>Fórmula:C39H36N6O10Pureza:98%Forma y color:SolidPeso molecular:748.74BSJ-5-63
CAS:<p>BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.</p>Fórmula:C52H74ClN9O6S2Forma y color:SolidPeso molecular:1020.78PROTAC CDK9/CycT1 Degrader-2
<p>PROTAC CDK9/CycT1 Degrader-2 inhibits CDK9 with an IC50 of 45 nM [1].</p>Fórmula:C30H36N4O6S2Pureza:98%Forma y color:SolidPeso molecular:612.76CDK4/6-IN-5
CAS:<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Fórmula:C22H28ClFN6O4SForma y color:SolidPeso molecular:527.01CDK7-IN-1
CAS:<p>CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.</p>Fórmula:C28H35N7O3Forma y color:SolidPeso molecular:517.634ZNL-05-044
<p>ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay.</p>Fórmula:C21H22Cl2N6OSPureza:98%Forma y color:SolidPeso molecular:477.41CDK9-IN-27
<p>CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest.</p>Fórmula:C23H18ClN5O3Pureza:98%Forma y color:SolidPeso molecular:447.87CDK2/Bcl2-IN-1
<p>CDK2/Bcl2-IN-1 (compound 1) is a saponin-based inhibitor of CDK-2 (IC50=117.6 nM) that exhibits potent cytotoxic effects on cancer cells.</p>Fórmula:C35H56O10SPureza:98%Forma y color:SolidPeso molecular:668.88(R)-Enitociclib
CAS:<p>(R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.</p>Fórmula:C19H18F2N4O2SPureza:98.98%Forma y color:SoildPeso molecular:404.43CDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Fórmula:C19H27N7OForma y color:SolidPeso molecular:369.464YKL-5-124 TFA
CAS:<p>YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.</p>Fórmula:C30H34F3N7O5Forma y color:SolidPeso molecular:629.63bio-THZ1
CAS:<p>bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM).</p>Fórmula:C52H65ClN12O8SPureza:98%Forma y color:SolidPeso molecular:1053.673-Methylthienyl-carbonyl-JNJ-7706621
CAS:<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Fórmula:C14H14N6O3S2Forma y color:SolidPeso molecular:378.43CDK8/19-IN-3
<p>CDK8/19-IN-3 (compound 3-7) is a potent and selective inhibitor of CDK8 and CDK19. It can increase IL-10 levels and has potential for research in inflammatory bowel disease (IBD).</p>Fórmula:C20H23FN6O2Forma y color:SolidPeso molecular:398.434BLINK15
<p>BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.</p>Forma y color:Odour SolidPROTAC CDK9 degrader-11
CAS:<p>PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)</p>Fórmula:C39H48Cl2N10O5Forma y color:SolidPeso molecular:807.768CDK5-IN-1
CAS:<p>CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.</p>Fórmula:C24H25FN6O3SForma y color:SolidPeso molecular:496.56NecroIr2
<p>NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.</p>Fórmula:C46H30ClIrN6O2Forma y color:SolidPeso molecular:926.44Abemaciclib metabolite M18
CAS:<p>Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.</p>Fórmula:C25H28F2N8OPureza:98%Forma y color:SolidPeso molecular:494.54CDK9/EZH2-IN-1
CAS:<p>CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.</p>Fórmula:C47H59N11O4S2Forma y color:SolidPeso molecular:906.17CDK2 degrader 3
CAS:<p>CDK2 degrader3 selectively degrades CDK2 and exhibits antitumor activity.</p>Fórmula:C44H53ClN10O6SForma y color:SolidPeso molecular:885.47LSN3106729 hydrochloride
CAS:<p>LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.</p>Fórmula:C25H29ClF2N8OForma y color:SoildPeso molecular:531.00CDK9 ligand 3
CAS:<p>CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.</p>Fórmula:C18H18BrCl2N5O3Forma y color:SolidPeso molecular:503.177HS-243
CAS:<p>HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.</p>Fórmula:C17H16N4O3Pureza:98.62%Forma y color:SolidPeso molecular:324.33CDK9-IN-28
<p>PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor, serves as a target protein ligand for PROTAC synthesis.</p>Fórmula:C32H40N4O6S2Pureza:98%Forma y color:SolidPeso molecular:640.81PROTAC CDK9 degrader-6
CAS:<p>PROTAC CDK9 degrader-6 targets and degrades CDK9 isoforms via proteasome, with DC50 of 0.10μM and 0.14μM.</p>Fórmula:C42H49Cl2N9O8Pureza:98%Forma y color:SolidPeso molecular:878.8CDK12/13-IN-2
<p>CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.</p>Fórmula:C24H22FN7O2Forma y color:SolidPeso molecular:459.48PF07104091
CAS:<p>PF07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation. Cost-effective and quality-assured.</p>Fórmula:C19H28N6O4Pureza:99.49%Forma y color:SolidPeso molecular:404.46TMX-2039
CAS:<p>TMX-2039 is a pan-CDK inhibitor that targets cell cycle CDKs (CDK1, CDK2, CDK4, CDK5, and CDK6) and transcription CDKs (CDK7 and CDK9), with IC50 values of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5, and 25 nM, respectively. It serves as a ligand for the target protein in PROTAC applications.</p>Fórmula:C17H20BrFN6O3SForma y color:SolidPeso molecular:487.347NecroIr1
<p>NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.</p>Fórmula:C40H29ClIrN5OForma y color:SolidPeso molecular:823.36CDK8-IN-12
CAS:<p>CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.</p>Fórmula:C21H20ClN3O2Pureza:99.46% - 99.83%Forma y color:SoildPeso molecular:381.86A-130A
CAS:<p>A-130A is a polycyclic polyether compound belonging to the nigericin group of antibiotics generated by Streptomyces hygroscopicus strain.</p>Fórmula:C47H78O13Pureza:98%Forma y color:SolidPeso molecular:851.11CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Fórmula:C20H20BrF3N6O2Forma y color:SolidPeso molecular:513.319Roccellic Acid
CAS:<p>Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.</p>Fórmula:C17H32O4Forma y color:SolidPeso molecular:300.43CDK12-IN-4
CAS:<p>CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).</p>Fórmula:C20H20F2N8OForma y color:SolidPeso molecular:426.432IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Fórmula:C23H32FN5O2SiForma y color:SolidPeso molecular:457.625EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Fórmula:C49H32N12O2S2Pureza:98%Forma y color:SolidPeso molecular:884.99Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Pureza:98%Forma y color:Odour SolidCDK-TCIP2
<p>DK-TCIP2 is an anticancer agent formed by linking the CDK9 inhibitor SNS-032 and the BCL6 inhibitor BI-3812. This compound exhibits anticancer activity both in vivo and in vitro, making it suitable for research in lymphoma.</p>Fórmula:C52H67ClN12O8S2Forma y color:SolidPeso molecular:1087.75CDK2/4-IN-1
<p>CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.</p>Forma y color:Odour SolidEGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Fórmula:C24H16N6OS2Pureza:98%Forma y color:SolidPeso molecular:468.55CDK6/9-IN-1
CAS:<p>CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).</p>Fórmula:C22H25ClN8OForma y color:SolidPeso molecular:452.95CDK9-IN-26
<p>CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1]</p>Fórmula:C17H14N4O2Pureza:98%Forma y color:SolidPeso molecular:306.32BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Forma y color:Liquid(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Forma y color:SolidPeso molecular:513.38WAY-322243
CAS:<p>WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.</p>Fórmula:C18H18N2O2SPureza:99.88%Forma y color:SoildPeso molecular:326.41PROTAC CDK9 degrader-5
CAS:<p>PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.</p>Fórmula:C42H48Cl2N8O9Pureza:98%Forma y color:SolidPeso molecular:879.78CDK12-IN-2
CAS:<p>CDK12-IN-2 selectively inhibits CDK12 (IC50: 52 nM) with minimal effect on CDK2, CDK7, and CDK9, useful for CDK12 research.</p>Fórmula:C32H32N6O2Pureza:99.31%Forma y color:SolidPeso molecular:532.64PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Fórmula:C43H56N10O5Forma y color:SolidPeso molecular:792.973MB-PP1
CAS:<p>3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor.</p>Fórmula:C17H21N5Pureza:99.96%Forma y color:White SolidPeso molecular:295.38CDK7-IN-2 hydrochloride hydrate
CAS:<p>CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.</p>Fórmula:C26H42ClN7O4Forma y color:SolidPeso molecular:552.12CDK7/9-IN-1
CAS:<p>CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.</p>Fórmula:C24H32F3N5O2Forma y color:SolidPeso molecular:479.548Flavopiridol
CAS:<p>Flavopiridol (Alvocidib) blocks CDK1/2/4/6 by competing with ATP (IC50 ~40 nM); 7.5x selectivity over CDK7; also inhibits EGFR, PKA. In Phase 1/2 trials.</p>Fórmula:C21H20ClNO5Pureza:97.74% - 99.86%Forma y color:SolidPeso molecular:401.84WAY-647802
CAS:<p>WAY-647802 is a CDK inhibitor.</p>Fórmula:C11H14N4O3Pureza:99.53%Forma y color:SolidPeso molecular:250.25CDK-IN-12
CAS:<p>CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].</p>Fórmula:C26H29FN6OSForma y color:SolidPeso molecular:492.61CGP-74514
CAS:<p>CGP-74514,CDK1 inhibitor (IC50=25 nM). Induces G2/M arrest, apoptosis. Used in bladder cancer research.</p>Fórmula:C19H24ClN7Pureza:98.54%Forma y color:SoildPeso molecular:385.89CDK1-IN-2
CAS:<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Fórmula:C17H11ClN2OPureza:98.53%Forma y color:SoildPeso molecular:294.73CDK5-IN-3
CAS:<p>CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.</p>Fórmula:C22H26N4OPureza:98.21%Forma y color:SolidPeso molecular:362.47Palbociclib-d8
CAS:<p>Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.</p>Fórmula:C24H21D8N7O2Pureza:98%Forma y color:SolidPeso molecular:455.58NCT02
CAS:<p>NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.</p>Fórmula:C17H16N2O2SForma y color:SolidPeso molecular:312.39TG003
CAS:<p>TG003 is a Clk1/Sty inhibitor that inhibits Clk1 and Clk4, suppresses cancer cell growth, and induces apoptosis.</p>Fórmula:C13H15NO2SPureza:99.46%Forma y color:SolidPeso molecular:249.33GP-82996
CAS:<p>GP-82996 (CINK4) inhibits CDK4/6; IC50s: 1.5 μM (CDK4/D1), 5.6 μM (CDK6/D1), 25 μM (Cdk5/p35); triggers U2OS cancer cell apoptosis.</p>Fórmula:C27H32N6OPureza:99.94%Forma y color:SolidPeso molecular:456.58(E/Z)-Zotiraciclib hydrochloride
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3.</p>Fórmula:C23H25ClN4OForma y color:SolidPeso molecular:408.93LDC4297
CAS:<p>LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.</p>Fórmula:C23H28N8OPureza:98.25%Forma y color:SolidPeso molecular:432.52NU6102
CAS:<p>NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.</p>Fórmula:C18H22N6O3SPureza:99.76%Forma y color:SolidPeso molecular:402.47Palbociclib hydrochloride
CAS:<p>Palbociclib hydrochloride is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor for breast and hepatocellular carcinoma.</p>Fórmula:C24H31Cl2N7O2Pureza:99.89%Forma y color:SolidPeso molecular:520.46Ribociclib hydrochloride
CAS:<p>Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Fórmula:C23H31ClN8OPureza:98%Forma y color:SolidPeso molecular:471FMF-04-159-2
CAS:<p>FMF-04-159-2 is a potent covalent CDK14 & CDK2 inhibito and is able to reduce α-Syn aggregation in neurons, and inhibits TNBC cancer progression.</p>Fórmula:C28H30Cl3N7O5SPureza:96.57%Forma y color:SolidPeso molecular:683.01Ribociclib-d6
CAS:<p>Ribociclib-d6 is a deuterated compound of Ribociclib (LEE011) for isotope tracing.Ribociclib is an orally available CDK4/6 inhibitor with antitumor activity.</p>Fórmula:C23H30N8OForma y color:SolidPeso molecular:440.57CDK9-IN-1
CAS:<p>CDK9-IN-1 is a selective and potent CDK9 inhibitor with antiviral activity used in the study of PRRSV infections.</p>Fórmula:C26H21N5O4SPureza:98.52%Forma y color:SolidPeso molecular:499.54Dalpiciclib hydrochloride
<p>Dalpiciclib (SHR-6390) HCl is an oral CDK4/6 inhibitor with IC50s of 12.4/9.9 nM, an antitumor for breast and esophageal cancers.</p>Fórmula:C25H31ClN6O2Forma y color:SolidPeso molecular:483.01Atuveciclib
CAS:<p>Atuveciclib Racemate is an oral CDK9 inhibitor with a 13 nM IC50, targeting P-TEFb/CDK9 selectively.</p>Fórmula:C18H18FN5O2SPureza:98.8%Forma y color:SolidPeso molecular:387.43Avotaciclib trihydrochloride
CAS:<p>Avotaciclib trihydrochloride (BEY1107) is an oral CDK1 inhibitor targeting advanced pancreatic cancer.</p>Fórmula:C13H14Cl3N7OPureza:99%Forma y color:SolidPeso molecular:390.65DRB
CAS:<p>DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM)</p>Fórmula:C12H12Cl2N2O4Pureza:99.46% - 99.83%Forma y color:White To Off-White Crystalline SolidPeso molecular:319.14Senexin A
CAS:<p>Senexin A is an effective and selective CDK8 inhibitor that also inhibits CDK19 with Kd values of 0.83 microns and 0.31 microns, respectively.</p>Fórmula:C17H14N4Pureza:99.74%Forma y color:SolidPeso molecular:274.32LDC-4297 HCl (1453834-21-3(free base))
<p>LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.</p>Fórmula:C23H29ClN8OPureza:100%Forma y color:SolidPeso molecular:469.02LY3143921
CAS:<p>LY3143921 ((S)-Example 2) is an orally active inhibitor of CDC7 kinase with broad in vitro anticancer activity [1].</p>Fórmula:C16H12FN5OForma y color:SolidPeso molecular:309.3Cdk5 Substrate acetate
<p>Cdk5, a serine/threonine kinase active in neurons, phosphorylates proteins like histone H1; its synthetic substrate has a Km of 5 µM.</p>Fórmula:C55H103N15O14Pureza:96.21%Forma y color:SolidPeso molecular:1198.5AMG 925 HCl
CAS:<p>AMG 925 HCl is a selective and potent dual inhibitor of FLT3 (IC50: 2±1 nM) and CDK4 (IC50: 3±1 nM).</p>Fórmula:C26H30ClN7O2Forma y color:SolidPeso molecular:508.02PF-06873600
CAS:<p>PF-06873600: oral CDK inhibitor (CDK2/4/6), Ki 0.09-0.16 nM, potential anticancer drug.</p>Fórmula:C20H27F2N5O4SPureza:98.77% - 99.55%Forma y color:SolidPeso molecular:471.52MLS-573151
CAS:<p>MLS-573151 is a selective inhibitor of GTPase Cdc42(EC50 of 2 μM).</p>Fórmula:C21H19N3O2SPureza:98.80%Forma y color:SolidPeso molecular:377.46CDK9-IN-30
CAS:<p>CDK9-IN-30 is one of the Tat peptide derivatives and inhibits HIV-1 long terminal repeat-activated transcription.</p>Fórmula:C16H20FNO3Pureza:99.75%Forma y color:SolidPeso molecular:293.33AZD-5438
CAS:<p>AZD-5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM).</p>Fórmula:C18H21N5O2SPureza:99.73% - 99.87%Forma y color:SolidPeso molecular:371.46Flavopiridol hydrochloride
CAS:<p>Flavopiridol hydrochloride (MDL 107826A), an inhibitor of cyclin-dependent kinase, is a synthetic N-methylpiperidinyl chlorophenyl flavone compound.</p>Fórmula:C21H21Cl2NO5Pureza:98.87% - 99.88%Forma y color:SolidPeso molecular:438.3PHA-767491 hydrochloride
CAS:<p>PHA-767491 (CAY-10572) is a potent Cdc7/CDK9 inhibitor (IC50: 10/34 nM), selective against GSK3-β, CDK1/2, CDK5, MK2, CHK2, PLK1.</p>Fórmula:C12H12ClN3OPureza:99.56% - 99.92%Forma y color:SolidPeso molecular:249.69Seliciclib
CAS:<p>Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E, also inhibits Cdk7, Cdk5 and Cdc2. Seliciclib has antitumor effect. Cost-effective, quality assurance.</p>Fórmula:C19H26N6OPureza:97.15% - 99.89%Forma y color:White To Off-White SolidPeso molecular:354.45BSJ-03-123
CAS:<p>BSJ-03-123 is a potent, CDK6-selective small-molecule degrader.</p>Fórmula:C47H56N10O11Pureza:97.78% - 99.38%Forma y color:SolidPeso molecular:937.01(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Forma y color:SolidPeso molecular:372.46AG-494
CAS:<p>AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.</p>Fórmula:C16H12N2O3Pureza:98.69%Forma y color:SolidPeso molecular:280.28Indirubin-3'-monoxime
CAS:<p>Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/</p>Fórmula:C16H11N3O2Pureza:99.55%Forma y color:Dark Red SolidPeso molecular:277.28JSH-150
CAS:<p>JSH-150 is a highly selective CDK9 inhibitor(IC50 : 1 nM).</p>Fórmula:C24H33ClN6O2SPureza:99.96% - 99.96%Forma y color:SolidPeso molecular:505.08Dinaciclib
CAS:<p>Dinaciclib (SCH 727965) is a CDK inhibitor that selectively inhibits CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM).</p>Fórmula:C21H28N6O2Pureza:98.21% - 99.75%Forma y color:SolidPeso molecular:396.49THZ1 Hydrochloride
<p>THZ1 Hydrochloride: selective covalent CDK7 inhibitor, IC50 of 3.2 nM; affects CDK12/13 & lowers MYC expression.</p>Fórmula:C31H29Cl2N7O2Forma y color:SolidPeso molecular:602.51PHA-767491
CAS:<p>PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.</p>Fórmula:C12H11N3OPureza:99.49% - >99.99%Forma y color:SolidPeso molecular:213.24THZ1
CAS:<p>THZ1 (CDK7 inhibitor) is a selective inhibitor of CDK7, binding to the Cys residue located at the outer end of the classical kinase domain. Cost-effective and quality-assured.</p>Fórmula:C31H28ClN7O2Pureza:95.09% - 99.27%Forma y color:SolidPeso molecular:566.05Bromosporine
CAS:<p>Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.</p>Fórmula:C17H20N6O4SPureza:99.65% - 99.79%Forma y color:SolidPeso molecular:404.447BIO
CAS:<p>7BIO triggers nonapoptotic death, blocks FLT3, DYRK1A/2, Aurora B/C kinases.</p>Fórmula:C16H10BrN3O2Pureza:99.67%Forma y color:SolidPeso molecular:356.17Briciclib
CAS:<p>Briciclib (ON 014185) is a small molecule that suppresses cyclin D1 accumulation in Y cells.</p>Fórmula:C19H23O10PSPureza:98% - 99.84%Forma y color:SolidPeso molecular:474.42BS-181 dihydrochloride
CAS:<p>BS-181 dihydrochloride: Potent CDK7 inhibitor (IC50: 21 nM), less effective on CDK2/5/9, no impact on CDK1/4/6, halts cancer cell growth, triggers apoptosis.</p>Fórmula:C22H34Cl2N6Forma y color:SolidPeso molecular:453.462-Chloropyrazine
CAS:<p>2-Chloropyrazine is used in chemical industry.</p>Fórmula:C4H3ClN2Pureza:98.98% - 99.89%Forma y color:Clear Colorless To Yellowish LiquidPeso molecular:114.53(E/Z)-Zotiraciclib citrate
<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) citrate is a potent inhibitor of CDK2, JAK2 and FLT3 and can be used in cancer research.</p>Fórmula:C29H32N4O8Forma y color:SolidPeso molecular:564.59ON-013100
CAS:<p>ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.</p>Fórmula:C19H22O7SPureza:98.27%Forma y color:SolidPeso molecular:394.44FIT-039
CAS:<p>FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1).</p>Fórmula:C17H18FN3SPureza:98.61%Forma y color:SolidPeso molecular:315.41RGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Fórmula:C29H35N7O4Pureza:98% - 99.91%Forma y color:SolidPeso molecular:545.63BMS-265246
CAS:<p>BMS-265246 is a potent and selective CDK1/2 inhibitor.</p>Fórmula:C18H17F2N3O2Pureza:99.25% - 99.57%Forma y color:SolidPeso molecular:345.34SR-4835
CAS:<p>SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (</p>Fórmula:C21H20Cl2N10OPureza:98.09% - >99.99%Forma y color:SolidPeso molecular:499.36KB-0742 dihydrochloride
CAS:<p>KB-0742 dihydrochloride is a potent, selective and orally inhibitor of CDK9.</p>Fórmula:C16H27Cl2N5Pureza:99.79%Forma y color:SolidPeso molecular:360.33LY3405105
CAS:<p>LY3405105 (1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-</p>Fórmula:C26H39N7O3Pureza:99.66%Forma y color:SolidPeso molecular:497.63HQ461
CAS:<p>HQ461, a molecular glue, boosts CDK12-DDB1 binding, lowers cyclin K, impedes CDK12 phosphorylation, hinders DNA repair genes, and induces cell death.</p>Fórmula:C15H15N5OS2Pureza:98.11%Forma y color:SolidPeso molecular:345.44AT7519 Hydrochloride
CAS:<p>AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.</p>Fórmula:C16H18Cl3N5O2Pureza:99.66% - 99.9%Forma y color:SolidPeso molecular:418.71Fadraciclib
CAS:<p>Fadraciclib (CYC065) is an orally available, second-generation ATP-competitive inhibitor of CDK2/CDK9 kinases (IC50s: 5/26 nM).</p>Fórmula:C21H31N7OPureza:99.75%Forma y color:SolidPeso molecular:397.52Cucurbitacin E
CAS:<p>Cucurbitacin E, from Cucumic melo, inhibits cyclin B1/CDC2, and has neuroprotective, anti-proliferative, anti-cancer, and pain relief properties.</p>Fórmula:C32H44O8Pureza:98.88% - 99.87%Forma y color:SolidPeso molecular:556.69MSC2530818
CAS:<p>MSC2530818 is an effective, selective and orally available CDK8 inhibitor (IC50: 2.6 nM).</p>Fórmula:C18H17ClN4OPureza:98.93%Forma y color:SolidPeso molecular:340.81CKI-7
CAS:<p>CKI-7 is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor.</p>Fórmula:C11H14Cl3N3O2SPureza:>99.99%Forma y color:SolidPeso molecular:358.67Amantadine
CAS:<p>Amantadine (1-Aminoadamantane), an antiviral, is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release and blocks dopamine reuptake.</p>Fórmula:C10H17NPureza:99.73% - 99.94%Forma y color:Hexakistetrahedral Crystals By Sublimation SolidPeso molecular:151.25Abemaciclib methanesulfonate
CAS:<p>Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).</p>Fórmula:C27H32F2N8·CH4O3SPureza:98.69% - 99.44%Forma y color:SolidPeso molecular:602.7Desmethylglycitein
CAS:<p>Desmethylglycitein (6,7,4'-Trihydroxyisoflavone) , is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has</p>Fórmula:C15H10O5Pureza:97.93%Forma y color:SolidPeso molecular:270.24LY3177833
CAS:<p>LY3177833 is an Cdc7 kinase inhibitor (IC50 : 3.3 nM)</p>Fórmula:C16H12FN5OPureza:99.87%Forma y color:SolidPeso molecular:309.3SCH900776 (S-isomer)
CAS:<p>SCH900776 S-isomer (MK-8776 S-isomer) is an effective, specific and orally bioavailable inhibitor of checkpoint kinase Chk1 (IC50: 3 nM).</p>Fórmula:C15H18BrN7Pureza:99.88%Forma y color:SolidPeso molecular:376.25Dalpiciclib
CAS:<p>Dalpiciclib (SHR-6390) selectively inhibits CDK4/6 (IC50: 12.4/9.9 nM), is orally available, and impedes esophageal cancer growth.</p>Fórmula:C25H30N6O2Pureza:99.69%Forma y color:SolidPeso molecular:446.54BUR1
CAS:<p>BUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.</p>Fórmula:C16H17N5Pureza:90%Forma y color:SolidPeso molecular:279.34SNS-032
CAS:<p>SNS-032 (BMS-387032) is a selective inhibitor of CDK2 and is 10- and 20-fold selective over CDK1/CDK4. SNS-032 is sensitive to CDK7/9, and no effect on CDK6.</p>Fórmula:C17H24N4O2S2Pureza:98.27% - 99.91%Forma y color:SolidPeso molecular:380.53CC-671
CAS:<p>CC-671 is a dual TTK protein kinase (IC50: 0.005 μM) /CLK2 (IC50: 0.006 μM) inhibitor.</p>Fórmula:C28H28N6O4Pureza:98.66% - 98.8%Forma y color:SolidPeso molecular:512.56NVP-LCQ195
CAS:<p>NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).</p>Fórmula:C17H19Cl2N5O4SPureza:99.56% - 99.85%Forma y color:SolidPeso molecular:460.33Aminopurvalanol A
CAS:<p>Aminopurvalanol A is a competitive, selective and cell-permeable inhibitor of cyclin-dependent kinase (CDK) that potently inhibits Cyclin A/cdk2, Cyclin B/cdk1</p>Fórmula:C19H26ClN7OPureza:99.73%Forma y color:SolidPeso molecular:403.91
![[Ala92]-p16 (84-103)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP2133.webp&w=3840&q=75)
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
